Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene

Cancer Research

Volumn 56, Issue 6, 1996, Pages 1331-1340

  Chen, Ling ^a,b   Waxman, David J ^a   Chen, Dongshu ^b   Kufe, Donald W ^b  

^a Boston University   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; IFOSFAMIDE; METYRAPONE;

ALKYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL CONTACT; DRUG EFFECT; DRUG SENSITIVITY; ENZYME INACTIVATION; GENE ACTIVATION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; SENSITIZATION;

EID: 0029897684     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Moolten, F. L Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther., 1: 279-287, 1994.
2. Culver, K. W., and Blaese, R. M Gene therapy for cancer. Trends Genet , 10: 174-178, 1994.
3. Moolten, F. L., and Wells, J M. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst., 82: 297-300, 1990
4. Ezzeddine, Z. D., Martuza, R. L., Platika, D., Short, M. P., Malick, A , Choi, B., and Breakefield, X O. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol., 3: 608-614, 1991.
5. Mullen, C A , Kilstrup, M , and Blaese, R. M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl. Acad. Sci. USA, 89: 33-37, 1992.
6. Huber, B. E., Austin, E. A., Good, S. S., Knick, V. C., Tibbels, S., and Richards, C. A. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res., 53: 4619-4626, 1993.
7. Mullen, C. A., Coale, M. M., Lowe, R., and Blaese, R. M. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor Cancer Res., 54: 1503-1506, 1994.
8. LeBlanc, G. A , and Waxman, D J. Interaction of anticancer drugs with hepatic monooxygenase enzymes Drug Metab. Rev., 20: 395-439, 1989.
9. Chen, L., and Waxman, D. J. Metabolic activation of anticancer oxazaphosphorines by cytochrome P450s: development of a model for cancer gene therapy. In: M. R. Waterman and M. Hildebrand (eds.), Assessment of the Use of Single Cytochrome P450 Enzymes in Drug Research, Vol. 13, pp 57-80 Berlin Springer-Verlag, 1994.
10. Sladek, N E Metabolism of oxazaphosphorines Pharmacol Ther., 37 301-355, 1988.
11. Pichard, L., Fabre, I., Daujat, M., Domergue, J., Joyeux, H., and Maurel, P. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol. Pharmacol., 41: 1047-1055, 1992
12. Sladek, N. E. Therapeutic efficacy of cyclophosphamide as a function of its metabolism. Cancer Res., 32: 535-542, 1972.
13. Faber, O. K , Mouridsen, H. T , and Skovsted, L The biotransformation of cyclophosphamide in man: influence of prednisone. Acta Pharmacol. Toxicol , 35: 195-200, 1974.
14. Moore, M. J. Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet., 20: 194-208, 1991
15. Clarke, L., and Waxman, D J. Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation Cancer Res , 49: 2344-2350, 1989
16. Weber, G. F., and Waxman, D. J. Activation of the anti-cancer drug ifosfamide by rat liver microsomal P450 enzymes. Biochem. Pharmacol., 45: 1685-1694, 1993.
17. Chang, T. K H , Weber, G. F., Crespi, C. L., and Waxman, D. J Differential activation of cyclophosphamide and ifosfamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res., 53: 5629-5637, 1993.
18. Walker, D , Flinois, J. P , Monkman, S C., Beloc, C., Boddy, A V , Cholerton, S , Daly, A. K., Lind, M J , Pearson, A D J., Beaune, P H , and Idle, J R. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem. Pharmacol., 47: 1157-1163, 1994.
19. Peters, W P , Ross, M , Vredenburgh, J. J., Meisenberg, B., Marks, L. B , Winer, E , Kurtzberg, J., Bast, R. C., Jr., Jones, R., and Shpall, E High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J. Clin Oncol , 11 1132-1143, 1993.
20. Ayash, L. J., Wright, J. E , Tretyakov, O., Gonin, R , Elias, A., Wheeler, C., Eder, J. P , Rosowsky, A., Antman, K , and Frei, E., III. Cyclophosphamide pharmacokinetics. correlation with cardiac toxicity and tumor response. J. Clin. Oncol , 10. 995-1000, 1992.
21. Chen, T L., Passos-Coelho, J. L., Noe, D. A , Kennedy, M. J., Black, K C , Colvin, O. M , and Grochow, L. B. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res., 55, 810-816, 1995.
22. Goren, M P., Wright, R. K , Pratt, C B , and Pell, F. E. Dechloroethylation of ifosfamide and neuroloxicity Lancet, 2: 1219-1220, 1986
23. Thigpen, T. Ifosphamide-induced central nervous system toxicity Gynecol Oncol., 42 191-192, 1991.
24. Chen, L., and Waxman, D J. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res., 55: 581-589, 1995.
25. Wei, M X., Tamiya, T , Chase, M., Boviatsis, E. J., Chang, T K. H., Kowall, N W., Hochberg, F. H., Waxman, D J , Breakefield, X. O., and Chiocca, E A Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther., 5 969-978, 1994
26. Scudiero, D. A., Shoemaker, R. H , Paull, K. D., Monks, A., Tierney, S., Nofziger, T. H., Currens, M. J., Seniff, D., and Boyd, M. R. Evaluation of a soluble tetrazolium/ formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines Cancer Res., 48: 4827-4833, 1988.
27. Graham, F. L., and Prevec, L Manipulation of adenovirus vectors. In: E J. Murray (ed.) Methods in Molecular Biology, Gene Transfer and Expression Protocols. Vol. 7, pp. 109-127. Clifton, NJ: The Human Press, Inc., 1991.
28. Chen, L., Chen, D , Manome, Y., Dong, Y., Fine, H. A., and Kufe, D. W. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J. Clin Invest., 96: 2775-2782, 1995.
29. McGrory, W. J , Bautista, D. S., and Graham, F. L. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology, 163: 614-617, 1988.
30. Waxman, D J. Rat hepatic cytochrome P-450 isoenzyme 2c. Identification as a male-specific, developmentally induced steroid 16 α-hydroxylase and comparison to a female-specific cytochrome P-450 isoenzyme. J. Biol. Chem., 259 15481-15490, 1984.
31. Waxman, D. J , and Walsh, C. Phenobarbital-induced rat liver cytochrome P450. Purification and characterization of two closely related isozymic forms. J. Biol. Chem., 257: 10446-10457, 1982.
32. Waxman, D. J., and Walsh, C. Cytochrome P-450 isozyme 1 from phenobarbital-induced rat liver: purification, characterization, and interactions with metyrapone and cytochrome b5. Biochemistry, 22: 4846-4855, 1983.
33. Ali, M., Lemoine, N. R., and Ring, C. J. A. The use of DNA viruses as vectors for gene therapy. Gene Ther., I: 367-384, 1994.
34. Chen, G., and Waxman, D. J. Identification of glutathione S-transferase as a determinant of 4-hydroperoxycyclophosphamide resistance in human breast cancer cells. Biochem. Pharmacol., 49: 1691-1701, 1995.
35. Cox, P. J., Farmer, P. B., Jarman, M., Kinas, R. W , and Stec, W. J. Stereoselectivity in the metabolism of the enantiorners of cyclophosphamide in mice, rats, and rabbits. Drug Metab. Dispos. Biol Fate Chem , 6 617-622, 1978.
36. Bullock, G., Tang, C., Tourkina, E., Ibrado, A M., Lutzky, J , Huang, Y., Mahoney, M. E., and Bhalla, K. Effect of combined treatment with interleukin-3 and interleukin-6 on 4-hydroperoxycyclo-phosphamide-induced programmed cell death or apoptosis in human myeloid leukemia cells. Exp. Hematol., 21: 1640-1647, 1993.
37. Hengstler, J. G., Fuchs, J., and Oesch, F. DNA strand breaks and DNA cross-links in peripheral mononuclear blood cells of ovarian cancer patients during chemotherapy with cyclophosphamide/carboplatin. Cancer Res., 52: 5622-5626, 1992.
38. Maccubbin, A. E., Caballes, L., Riordan, J. M., Huang, D. H., and Gurtoo, H. L. A cyclophosphamide/DNA phosphoester adduct formed in vitro and in vivo [published erratum appears in Cancer Res., 51: 3829, 1991]. Cancer Res., 51: 886-892, 1991.
39. Hemminki, K. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice. Cancer Res , 45: 4237-4243, 1985.
40. 2 arrest in Chinese hamster ovary cells Cancer Res., 50: 3761-3766, 1990.
41. 2 phase and cell death induced by cisplatin. J. Natl. Cancer Inst., 82: 749-755, 1990.
42. Davidoff, A. N., and Mendelow, B V Cell-cycle disruptions and apoptosis induced by the cyclophosphamide derivative mafosfamide. Exp Hematol., 21: 922-927, 1993
43. Tapscott, S. J , Miller, A. D , Olson, J M., Berger, M. S., Groudine, M., and Spence, A. M. Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection Proc. Natl. Acad. Sci USA, 91: 8185-8189, 1994.
44. Caruso, M., Panis, Y., Gagandeep, S., Houssin, D., Salzmann, J. L., and Klatzmann, D. Regression of established macroscopic liver metastases after in situ transaction of a suicide gene Proc. Natl Acad. Sci. USA, 90: 7024-7028, 1993.
45. Culver, K W , Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E H., and Blaese, R M In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science (Washington DC), 256: 1550-1552, 1992.
46. Kozarsky, K. F., and Wilson, J. M. Gene therapy: adenovirus vectors. Curr. Opin Genet. Dev., 3: 499-503, 1993.
47. Bett, A. J., Haddara, W., Prevec, L., and Graham, F. L. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc. Natl. Acad. Sci. USA, 91: 8802-8806, 1994.
48. Graham, F L., Smiley, J., Russel, W. C., and Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol , 36: 59-72, 1977.
49. Chen, S H., Shine, H. D., Goodman, J C , Grossman, R. G., and Woo, S L Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl. Acad. Sci. USA, 91: 3054-3057, 1994
50. O'Malley, B. W J., Chen, S. H., Schwartz, M. R., and Woo, S. L. C Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model Cancer Res., 55: 1080-1085, 1995.
51. Harris, J. D., Gutierrez, A A., Hurst, H. C., Sikora, K., and Lemoine, N. R. Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther., I: 170-175, 1994
52. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J , Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Washington DC), 235: 177-182, 1987.
53. Kufe, D. G , Inghirami, M., Abe, D., Hayes, D., and Justi-Wheeler, H. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma, 3: 223-232, 1984.
54. Hollywood, D. P., and Hurst, H. C. A novel transcription factor, OB2-1, is required for overexpression of the proto-oacogene c-erbB-2 in mammary tumour lines. EMBO J , 12: 2369-2375, 1993.
55. Kovarik, A., Peat, N , Wilson, D., Gendler, S. J , and Taylor-Papadimitriou, J Analysis of the tissue-specific promoter of the MUC1 gene. J Biol. Chem., 268: 9917-9926, 1993.
56. Abe, M., and Kufe, D. Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene. Proc. Natl. Acad. Sci. USA, 90: 282-286, 1993.
57. Manome, Y., Abe, M., Hagen, M. F., Fine, H. A., and Kufe, D. W. Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir. Cancer Res., 54: 5408-5413, 1994.
58. Bi, W. L., Parysek, L. M., Warnick, R., and Stambrook, P. J. in vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum. Gene Ther., 4: 725-731, 1993.
59. Freeman, S M., Afaboud, C N., Whartenby, K. A., Packman, C. H., Koeplin, D. S., Moolten, F. L., and Abraham, G. N. The "bystander effect", tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res., 53: 5274-5283, 1993.
60. Reid, R., Eng-Chun, M., Eng-Shang, H., and Topal, M. D. Insertion and extension of acyclic, dideoxy, and ara nucleotides by herpesviridae, human α and human β polymerases. J. Biol. Chem , 263: 3898-3904, 1988.